Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Feasibility of Akkermansia Probiotics Combined With Anti-PD-1 Monoclonal Antibody in MSS/pMMR Advanced Colorectal Cancer

NCT06865521 is registered in ClinicalTrials.gov with West China Hospital as lead sponsor.

NCT NCT06865521
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06865521 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Feasibility of Akkermansia Probiotics Combined With Anti-PD-1 Monoclonal Antibody in MSS/pMMR Advanced Colorectal Cancer
Lead sponsor
West China Hospital
Phase
Not applicable
Overall status
Active, not recruiting
Start date
February 21, 2025
Completion date
March 22, 2027
Enrollment
22 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

akkermansia muciniphila, colo-rectal cancer, pd-1 inhibitor